The first clinical application of McAb in Wanle pharmaceutical, a subsidiary of Sinopharm

According to the information on July 18 on the website of CFDA, Shenzhen Wanle Pharmaceutical Co., Ltd., a subsidiary of CFDA, has accepted the application of class 2 therapeutic biological products for injection recombinant anti HER2 humanized monoclonal antibody, which is the first single antibody variety uniformly applied by CFDA Recombinant anti HER2 humanized monoclonal antibody for injection is a heavyweight product for the treatment of breast cancer It is the original research drug of Roche pharmaceutical in Switzerland Its trade name is Herceptin In 2011, its global sales reached US $5.9 billion The cost of a course of treatment is about US $32000, and the cost of treatment is extremely high As an excellent targeted anti breast cancer drug, the drug has high clinical recognition, fierce competition in drug application, and the consistent participation of Chinese drugs, which further intensifies the industry competition pattern of the drug Fosun Pharmaceutical and CITIC Guojian, which Lansheng shares in, are the first to apply for the drug However, due to the difficulty of copying, there is no generic drug listed in China at present CITIC Guojian is far ahead and is expected to be approved for production within this year Shenzhen Wanle Pharmaceutical Co., Ltd is a state-level high-tech enterprise specialized in the development, production and sales of anti-tumor products, ranking second in the overall anti-tumor production enterprises in China, and is an important anti-tumor platform for national medicine.